Eli Lilly and (LLY)

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.

Eli Lilly (LLY -1.36%) stock investors need to be aware of these details before making a decision to buy or sell the stock.

Eli Lilly (LLY -1.36%) is one of my best stocks to buy in 2025.

I invest for long-term total return, focusing on high-quality, dividend-paying industry leaders with strong financials and consistent performance. Despite current headwinds like tariffs and patent exp...

Key Points in This Article: Dividend growth investing offers stable income and capital appreciation through compounding returns.

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.

I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbou...

After crushing the market over the past few years, Eli Lilly (LLY 2.73%) is finally feeling the effects of gravity. The company has faced a pair of setbacks this year.